Citadel Advisors’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Citadel Advisors’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-584,130	Closed	-$5.99M	–	15578
2023 Q2	$5.99M	Sell	584,130 -143,192	-20%	-$1.46M	﹤0.01%	3363
2023 Q1	$7.36M	Buy	727,322 +5,862	+0.8%	+$59K	﹤0.01%	3208
2022 Q4	$7.21M	Buy	721,460 +425	+0.1%	+$4.18K	﹤0.01%	3283
2022 Q3	$6.99M	Buy	721,035 +94	+0%	+$914	﹤0.01%	3322
2022 Q2	$6.99M	Buy	720,941 +125,000	+21%	+$1.22M	﹤0.01%	3210
2022 Q1	$5.81M	Buy	595,941 +2	+0%	+$19	﹤0.01%	3887
2021 Q4	$5.85M	Sell	595,939 -15,978	-3%	-$157K	﹤0.01%	4030
2021 Q3	$6.01M	Buy	+611,917	New	+$6.05M	﹤0.01%	3957

Citadel Advisors's DALS Position: Q3 2023 in Review

Citadel Advisors sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 584,130 shares — an estimated $5.99M sold.

Citadel Advisors first reported a position in DALS in Q3 2021 and held it in 8 quarters. The position peaked at $7.36M in Q1 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

Citadel Advisors reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 584,130 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $5.99M.
Citadel Advisors first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 8 quarters.
Citadel Advisors's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $7.36M in Q1 2023.
0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.